articleTop 1% cited
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
European Journal of Cancer · 2016 · Vol. 60 · pp. 210–225
Lisa Zimmer(University of Duisburg-Essen)Simone M. Goldinger(University Hospital of Zurich)Lars Hofmann(Friedrich-Alexander-Universität Erlangen-Nürnberg)Carmen Loquai(Johannes Gutenberg University Mainz)Selma Ugurel(University of Duisburg-Essen)Ioannis Thomas(University Children's Hospital Tübingen)Maria Isabel Schmidgen(Johannes Gutenberg University Mainz)Ralf Gutzmer(Medizinische Hochschule Hannover)Jochen Utikal(German Cancer Research Center)Daniela Göppner(University Hospital Magdeburg)Jessica C. Hassel(Heidelberg University)Friedegund MeierJulia K. Tietze(LMU Klinikum)Andrea Forschner(University Children's Hospital Tübingen)Carsten Weishaupt(University Hospital Münster)Martin Leverkus(RWTH Aachen University)R.U. Wahl(RWTH Aachen University)Ursula M. DietrichClaus Garbe(University Children's Hospital Tübingen)Michael Constantin Kirchberger(Friedrich-Alexander-Universität Erlangen-Nürnberg)Thomas Eigentler(University Children's Hospital Tübingen)Carola Berking(LMU Klinikum)Anja Gesierich(Universitätsklinikum Würzburg)Angela M. Krackhardt(Technical University of Munich)Dirk Schadendorf(University of Duisburg-Essen)Gerold Schuler(Friedrich-Alexander-Universität Erlangen-Nürnberg)Reinhard Dummer(University Hospital of Zurich)Lucie Heinzerling✉(Friedrich-Alexander-Universität Erlangen-Nürnberg)
Cancer Immunotherapy and BiomarkersMelanoma and MAPK PathwaysCAR-T cell therapy researchMedicineNivolumabPembrolizumabIpilimumabSide effect (computer science)Adverse effectCancerMyasthenia gravisMelanomaInternal medicine
MeSH terms
IpilimumabNivolumabAdultAgedAntibodies, MonoclonalAntineoplastic AgentsEye DiseasesFemaleHeart DiseasesHumansMaleMelanomaMiddle AgedMusculoskeletal DiseasesNervous System Diseases
Funding
- Amgen
Citations
556
FWCI
41.76
field-weighted impact
References
34
Percentile
100%
vs. same field & year
Citations per year
Cited by
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2017 · 2,321 citations
References
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Journal of Clinical Oncology · 2010 · 2,913 citations
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
New England Journal of Medicine · 2012 · 7,941 citations
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
The Lancet Oncology · 2015 · 1,421 citations
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Journal of Clinical Oncology · 2014 · 2,198 citations
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
The Lancet Oncology · 2015 · 2,648 citations
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · 8,491 citations
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
New England Journal of Medicine · 2012 · 12,531 citations
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
New England Journal of Medicine · 2015 · 8,055 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.